Wedbush lowered the firm’s price target on Xencor to $34 from $36 and keeps an Outperform rating on the shares after the company reported Q4/FY23 financial results and presented encouraging monotherapy data for vudalimab in mCRPC. Wedbush finds the results intriguing not only because of the high response rate among heavily pretreated patients, all of which had measurable disease, but also because of the lack of significant hematologic toxicity which supports a nonoverlapping AE profile for docetaxel combinations and/or sequencing relative to Pluvicto or other radioligand therapies.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on XNCR:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue